Menu
 

NEURO-APP CONFERENCE

ADVANCED CARE FOR NEUROSCIENCE PATIENTS

January 11-14, 2023 | Long Beach, CA OR Online

Industry Posters (Non-CE)

Sustained Seizure Freedom with Perampanel 4 mg/day Monotherapy in Patients with Newly Diagnosed/Currently Untreated Recurrent Focal-Onset Seizures, With/Without Focal to Bilateral Tonic-Clonic Seizures: Post Hoc Analysis of Study 342 (FREEDOM)

Authors: Manoj Malhotra, Ji Hyun Kim, Sung Chul Lim, Hirotomo Ninomiya, Takamichi Yamamoto, Anna Patten, Leock Y Ngo, Yuichi Kubota

View the poster

Sponsored by

NEW Eisai Logo cmyk 2


Adjunctive Perampanel for Generalized Tonic-Clonic Seizures: Time to Seizure Onset in Phase III Study 332

Authors: Manoj Malhotra, Anna Patten

View the poster

Sponsored by

NEW Eisai Logo cmyk 2


Once-Daily Valbenazine Is Effective for Tardive Dyskinesia in Elderly Patients (≥65 Years)

Older patients taking a dopamine-receptor blocking agent have increased risk for tardive dyskinesia (TD), a persistent and potentially disabling movement disorder. These analyses, being the first to assess the effects of an approved TD medication in elderly patients (≥65 years), indicate that long-term once-daily valbenazine is appropriate for this population.

View the poster

Sponsored by

neurocrine logo 2021 notag rgb

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Development of the MIND-TD Questionnaire as a Screening Tool for Tardive Dyskinesia

The MIND-TD questionnaire was developed to facilitate clinician-patient dialogues about the risks, symptoms, and impact of tardive dyskinesia (TD). Part 1 is a screening tool with questions about Movement, Impact, Notice, and Daily Activities. Part 2 includes a Thorough Interview and a Differentiation checklist to elicit more information about abnormal movements.

View the poster

Sponsored by

neurocrine logo 2021 notag rgb

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Evaluating Patients’ Preferences for Parkinson’s Disease Treatments

Pretest interviews were conducted to inform a broader survey on patient preferences for key attributes of adjunctive Parkinson’s disease medications. Most patients (10/15) reported they would add an adjunctive medication offering ~1.5 to 2 hours of additional “ON” time regardless of potential side effects and complication of preexisting medication regimens.

View the poster

Sponsored by

neurocrine logo 2021 notag rgb

Please forward all questions regarding our posters to medinfo@neurocrine.com.


Efficacy and Safety of Once-Daily Opicapone in Older Patients with Parkinson’s Disease and Motor Fluctuations

Pooled data from 2 pivotal Phase 3 studies of opicapone in patients with Parkinson’s disease (NCT01568073, NCT01227655) were analyzed to evaluate efficacy and safety of opicapone in older participants (≥65 years). Older participants had significantly greater improvements in “OFF”-time and “ON”-time with once-daily opicapone versus placebo; opicapone was generally well-tolerated.

View the poster

Sponsored by

neurocrine logo 2021 notag rgb

Please forward all questions regarding our posters to medinfo@neurocrine.com.